The short version
- Why people research itGeneralized anxiety (Russian phase III versus diazepam) and neuroprotection through sigma-1 receptors.
- What the evidence isOne randomized phase III comparison with diazepam and several older Russian studies.
- What to watchExcessive drowsiness or slowed thinking.
How Afobazole works
The mechanism is a sigma-1 story, with modest affinity.
It binds sigma-1 with micromolar affinity and moves the receptor within the cell, and in neurons it reduced calcium overload from simulated ischemia and acidosis through sigma-1, while in microglia it blocked migration and purinergic responses through both sigma-1 and sigma-2. It does not act at the benzodiazepine site of GABA-A and in the one randomized comparison with diazepam it caused far fewer adverse events and no withdrawal syndrome. Neuroprotective results in cell and mouse models, including a Parkinson's model, run through sigma-1.
- Oral
On the goal map: GABAergic & calming (Mood & stress resilience)
Research on Afobazole5 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Human (Russian randomized phase III versus diazepam, 150 patients; older Russian clinical studies); cell and animal mechanism work.
Human clinical evidence
One randomized phase III comparison with diazepam and several older Russian studies. In 150 adults with generalized anxiety disorder or adjustment disorders given afobazole or diazepam for 30 days, both lowered the Hamilton anxiety total but afobazole lowered it more (difference 2.93 points, p=0.01), 72 percent versus 58 percent improved, and the adverse event count was 15 versus 199, with no withdrawal syndrome in the afobazole group while 68 percent of diazepam patients had one (Syunyakov 2016). An earlier standardized study found the best effect in anxiety of simple structure and weaker effects in complex chronic disorders (Neznamov 2005).
The limits are the point. The comparator was an active drug, not placebo; patients who responded to a one-week placebo lead-in were excluded; the program is Russian; and no Western regulator has reviewed it. It shows afobazole is a plausible, well-tolerated anxiolytic in that population, not that it beats placebo.
Correlative data
A long registered-drug record in Russia. It has been prescribed there for years, including in anxiety with cardiovascular disease, but registries and pharmacovigilance reports are not in the indexed literature read here.
How the mechanism reads
The mechanism is a sigma-1 story, with modest affinity. Binding is at micromolar concentrations and moves the receptor out of the endoplasmic reticulum (Seredenin 2009); in neurons it reduced calcium overload from simulated ischemia and acidosis through sigma-1 (Cuevas 2011), in microglia it damped purinergic signaling through sigma-1 and sigma-2 (Cuevas 2011), and in a mouse Parkinson's model it spared dopaminergic neurons in a sigma-1-dependent way (Voronin 2019).
Experimental, animal or cellThe predicted downside is small and unmeasured. Sigma-1 ligands modulate several neurotransmitter systems, so additive sedation with other CNS drugs is the realistic caution. The 150-patient trial reported far fewer adverse events than diazepam, but a single trial of that size cannot rule out rarer problems.
Mechanistic
Afobazole safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Pregnancy or breastfeeding, since no safety data in either was found.
- Combining with benzodiazepines, alcohol or other sedatives without a plan, because additive CNS depression is the realistic interaction.
- Serious liver disease, as the drug and its main metabolite are processed there.
- Under 18.
What’s expected
- Mild daytime calm without sedation is what the trial describes.
- Occasional headache or stomach upset: the trial counted far fewer adverse events than diazepam.
Watch for
- Excessive drowsiness or slowed thinking.
- A rash or itching, which points to an allergic reaction.
- Worsening anxiety or low mood.
Labs that tell you it’s working
- Comprehensive Metabolic Panel: liver enzymes for a hepatically cleared drug.
- Cortisol: anxiety and stress axis, a secondary readout of whether the effect is real.
- Thyroid-stimulating hormone: thyroid disease imitates anxiety and has to be excluded first.
Sigma-1 agonist anxiolytic with a randomized trial versus diazepam in Russia; safety is read from that trial and from mechanism. PMID 27636931 PMID 19902093 PMID 21715562
Bloodwork to runHow you would know it is working: 6 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Afobazole FAQ4 common questions
- Is Afobazole approved for human use?
- No. Afobazole is a research compound.
- What is Afobazole researched for?
- Generalized anxiety (Russian phase III versus diazepam) and neuroprotection through sigma-1 receptors.
- Which labs show whether it's doing anything?
- Comprehensive Metabolic Panel; Cortisol; Thyroid-stimulating hormone: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Afobazole: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



